Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Polyethylene glycol + linaclotide is a combination regimen used primarily for bowel preparation prior to colonoscopy, especially in patients with chronic constipation or irritable bowel syndrome. Polyethylene glycol (PEG) is an osmotic laxative that retains water in the stool, resulting in softer stools and increased bowel movements. Linaclotide is a guanylate cyclase-C agonist that increases intestinal fluid secretion and accelerates transit by stimulating cyclic GMP production on the luminal surface of the intestinal epithelium. The combination aims to improve both efficacy and tolerability of bowel cleansing compared to high-volume PEG alone, offering similar or superior cleansing quality with reduced adverse effects such as abdominal discomfort, bloating, nausea, and vomiting[1][2][3][4][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on polyethylene glycol + linaclotide.